Changes in parameters between the two groups
Muscle mass (kg)-, end-stage liver disease
Comparisons of changes (delta, Δ) in clinical and laboratory parameters at baseline and week 16 between 2 groups is demonstrated in the Table 
Comparison of changes in parameters from baseline to week 16 between 2 groups∆ LFI- ∆ HGS (kg)- ∆ CST (sec)- ∆ Balancing test (sec)-0.36 ± 0.36.63 ± 3.77-9.28 ± 11.053.52 ± 3.18-0.15 ± 0.285.69 ± 3.13-2 ± 4.041.32 ± 3.490.010.52< 0.010.02- ∆ Muscle mass (kg)- ∆ SMI (kg/m- ∆ Fat free mass (kg)0.52 ± 1.310.21 ± 0.52-0.15 ± 2.36-0.03 ± 2.56-0.01 ± 1.040.40 ± 4.060.080.070.85*By non-parametric Mann–Whitney U testBMI, body mass index; MELD, model for end-stage liver disease; LFI, liver frailty index; HGS, hand grip strength; CST, chair stands test; SKI, skeletal muscle indexBy repeated measures ANOVA analysis using each outcome as the dependent variable and time, study group, and time-by-group interaction as the independent variables, BCAA group had a significant increase in LFI (P = 0.03), and serum albumin (P = 0.04), but not SMI (P = 0.53). Figure 
Comparison of changes of liver frailty index (Fig. 2A), serum albumin (Fig. 2B), and skeletal muscle index (Fig. 2C) over the 16-week follow-up period between 2 groups